Comparative Efficacy and Safety of the Non-Vitamin K Antagonist Oral Anticoagulants for Patients with Nonvalvular Atrial Fibrillation

被引:14
|
作者
Senoo, Keitaro [1 ]
Lip, Gregory Y. H. [1 ,2 ]
机构
[1] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham B18 7QH, W Midlands, England
[2] Aalborg Univ, Aalborg Thrombosis Res Unit, Dept Clin Med, Aalborg, Denmark
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2015年 / 41卷 / 02期
关键词
non-VKA oral anticoagulants; vitamin K antagonist; atrial fibrillation; stroke prevention; clinical trial; STROKE PREVENTION; SAME-TT2R2; SCORE; BLEEDING RISK; WARFARIN; RIVAROXABAN; APIXABAN; DABIGATRAN; MANAGEMENT; EDOXABAN; INSIGHTS;
D O I
10.1055/s-0035-1544156
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The non-vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor (dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have been shown to be at least as efficacious and safe as conventional oral anticoagulants, such as the vitamin K antagonists (VKAs) (e. g., warfarin), for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). Each NOAC has various advantages and specific features, and therefore decisions regarding appropriate stroke prevention require individual assessment of stroke and bleeding risk on anticoagulation with VKA therapy and NOACs when starting on any of these drugs. This review briefly describes the results of the four NOACs clinical randomized trials and discusses how they might impact clinical practice and choice of anticoagulants in atrial fibrillation patients. Moreover, this review discusses the differences of the proposed management of antithrombotic therapy in several international guidelines and pragmatic issues of NOACs for stroke prophylaxis.
引用
收藏
页码:146 / 153
页数:8
相关论文
共 50 条
  • [21] Safety and Efficacy of Non-Vitamin K Antagonist Oral Anticoagulants During Transcatheter Ablation of Atrial Fibrillation
    Ge, Zhen
    Faggioni, Michela
    Usman, Baber
    Farhan, Serdar
    Sorrentino, Sabato
    Vogel, Birgit
    Chandrasekhar, Jaya
    Snyder, Clayton
    Sartori, Samantha
    Qadeer, Abdul
    Reddy, Vivek
    Dukkipati, Srinivas
    Dangas, George
    Mehran, Roxana
    CIRCULATION, 2017, 136
  • [22] Efficacy and safety of non-vitamin K antagonist oral anticoagulants in renal transplant recipients with atrial fibrillation
    Heleniak, Zbigniew
    Naik, Marcel
    Eleftheriadis, Georgios
    Ruszkowski, Jakub
    Halleck, Fabian
    Undas, Anetta
    Debska-Slizien, Alicja
    Budde, Klemens
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2682 - I2683
  • [23] Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
    Middeldorp, Melissa E.
    Gupta, Aashray
    Elliott, Adrian
    Kadhim, Kadhim
    Thiyagarajah, Anand
    Gallagher, Celine
    Hendriks, Jeroen
    Linz, Dominik
    Emami, Mehrdad
    Mahajan, Rajiv
    Lau, Dennis
    Sanders, Prashanthan
    HEART, 2021, 107 (12) : 971 - 976
  • [24] Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation - in-group comparison
    Piasecki, Adam
    BIULETYN WYDZIALU FARMACEUTYCZNEGO WARSZAWSKIEGO UNIWERSYTETU MEDYCZNEGO, 2022, (01):
  • [25] Safety and Efficacy of Underdosing Non-vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Catheter Ablation for Atrial Fibrillation
    Yamaji, Hirosuke
    Murakami, Takashi
    Hina, Kazuyoshi
    Higashiya, Shunichi
    Kawamura, Hiroshi
    Murakami, Masaaki
    Kamikawa, Shigeshi
    Komatsubara, Issei
    Kusachi, Shozo
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2017, 69 (02) : 118 - 126
  • [26] EFFECTIVENESS AND SAFETY OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN OBESE NONVALVULAR ATRIAL FIBRILLATION PATIENTS: A POOLED CLAIMS DATABASE ANALYSIS
    Deitelzweig, Steven
    Keshishian, Allison
    Kang, Amiee
    Dhamane, Amol
    Luo, Xuemei
    Li, Xiaoyan
    Balachander, Neeraja
    Rosenblatt, Lisa
    Mardekian, Jack
    Pan, Xianying
    Di Fusco, Manuela
    Garcia, Alessandra Bassalobre
    Yuce, Huseyin
    Lip, Gregory Y. H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 434 - 434
  • [27] Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation
    Fanaroff, Alexander C.
    Ohman, E. Magnus
    ANNUAL REVIEW OF MEDICINE, VOL 70, 2019, 70 : 61 - 75
  • [28] Non-vitamin K antagonist oral anticoagulants in valvular atrial fibrillation
    Basaran, Ozcan
    Dogan, Volkan
    Sahin, Cem
    Biteker, Murat
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 357 - 357
  • [29] The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation
    Grymonprez, Maxim
    Petrovic, Mirko
    De Backer, Tine L.
    Steurbaut, Stephane
    Lahousse, Lies
    THROMBOSIS AND HAEMOSTASIS, 2024, 124 (02) : 135 - 148
  • [30] Safety of non-vitamin K antagonist oral anticoagulants: concerns in patients with atrial fibrillation and glomerular hyperfiltration?
    Huqi, Alda
    Zoccali, Carmine
    Giugliano, Robert P.
    De Caterina, Raffaele
    EUROPEAN HEART JOURNAL, 2023, 44 (04) : 322 - 325